Clinical Trial Update: SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Sanofi’s Phase 2 trial of SAR240550 in combination with gemcitabine and cisplatin for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• SAR240550

Snippet

Sponsor: Sanofi | Conditions: Non-small Cell Lung Cancer Stage IV | Phase 2 | Status: COMPLETED